Affiliate disclosure: some links on this page are affiliate links and may earn us a commission at no extra cost to you — it never affects our rankings or reviews.
Guide · Medicaid · United States
Does Medicaid cover Zepbound?
It depends on your state: as of October 30, 2026, most state Medicaid programs do not cover Zepbound for weight loss alone, and 10 of the 51 programs in the 50 states and DC cover GLP-1s such as Zepbound for weight loss, all with prior authorization. Medicaid still covers the FDA-approved uses it must cover, such as Zepbound for obstructive sleep apnea, subject to the state's prior authorization, and several states ended weight-loss coverage in 2026.
Every fact on this page carries its source and date; we read them on October 30, 2026. This is general information, not advice about your plan or your health: a clinician decides whether a medicine is right for you, and your state's Medicaid program decides coverage.
The short answer, state by state
- Covers GLP-1s such as Zepbound for weight loss, with prior authorization: Delaware, Kansas, Minnesota, Mississippi, Missouri, North Carolina, Tennessee and Wisconsin.
- Covers with much tighter criteria: Michigan and Virginia.
- Names Zepbound in the criteria we read: Delaware, Mississippi, North Carolina and Tennessee.
- Ended weight-loss coverage in 2026: California, Massachusetts, New Hampshire, Pennsylvania, Rhode Island and South Carolina; Utah is not confirmed.
- Pending, not live: Indiana and Louisiana.
- Every state: Medicaid still covers the FDA-approved uses it must cover, such as Zepbound for obstructive sleep apnea, subject to the state's prior authorization.
The full table, with every state's criteria and source, is in Medicaid GLP-1 coverage by state.
Where Medicaid covers Zepbound for weight loss
Status as of October 30, 2026. These 10 programs cover GLP-1s for obesity; "Limited" means the criteria are much tighter than the label. Where a state's criteria were not verified, the row says so. Your prescriber applies for prior authorization.
| State | Covers GLP-1s for weight loss? | Criteria | Source | Date |
|---|---|---|---|---|
| Delaware | Yes | BMI over 30, or over 27 with a related condition (type 2 diabetes, heart disease, high blood pressure, high cholesterol or sleep apnea). Lifestyle program required. 6-month approvals; renewal needs at least 5% weight loss. Saxenda, liraglutide, Wegovy, Zepbound. From a managed care plan policy aligned to the state plan. | Delaware First Health policy; KFF | reviewed Apr 2026; Jan 16, 2026 |
| Kansas | Yes (KFF) | Criteria not verified | KFF | Jan 16, 2026 |
| Michigan | Limited | Since Jan 1, 2026: "morbidly obese" only (no numeric BMI given), after all other interventions including preferred anti-obesity drugs have failed, to avoid bariatric surgery | MDHHS Numbered Letter L 25-73 | Dec 8, 2025 |
| Minnesota | Yes (KFF) | DHS prior authorization criteria page modified Aug 4, 2026; its body text could not be read | KFF; Minnesota DHS criteria page | Jan 16, 2026; modified Aug 4, 2026 |
| Mississippi | Yes | Adults: BMI 30 or higher, or 27 to 29 with a related condition. Foundayo, Saxenda, Wegovy and Zepbound preferred. Lifestyle program and treatment plan required. 12-month approvals; renewal needs at least 5% weight loss. Members with Part D must use Part D first. | Mississippi Medicaid criteria | Jul 1, 2026 |
| Missouri | Yes (KFF) | Criteria not verified | KFF | Jan 16, 2026 |
| North Carolina | Yes | Reinstated Dec 12, 2025 under the Aug 1, 2024 prior authorization criteria. Wegovy preferred; Zepbound and Saxenda need a Wegovy trial first. | NC Medicaid | Dec 19, 2025 |
| Tennessee | Yes | Adults: BMI 30 or higher, or 27 or higher with a related condition (high blood pressure, high cholesterol, diabetes, heart disease, MASH or sleep apnea). Wegovy and Zepbound preferred, with prior authorization. Lifestyle attestation; renewal needs at least 5% weight loss. | TennCare / OptumRx provider notice | effective Aug 1, 2025 |
| Virginia | Limited | GLP-1s: BMI over 40, or over 37 with high cholesterol, high blood pressure or type 2 diabetes. One non-GLP-1 weight-loss drug must fail first, plus a preferred drug list step. | DMAS weight loss PA form | revised Apr 16, 2026 |
| Wisconsin | Yes | Adults: BMI 30 or higher, or 27 to under 30 with two related conditions. A weight-loss plan in the prior 6 months. A July 2026 criteria update was reported by a secondary source and is not confirmed. | Wisconsin ForwardHealth PA form; KFF | form Jul 2024; Jan 16, 2026 |
Zepbound for sleep apnea: covered with prior authorization
Zepbound is also approved for moderate-to-severe obstructive sleep apnea in people with obesity. Where the manufacturer has a rebate agreement, states must cover Zepbound for that use (CMS, January 2025); they do not have to cover it for weight loss. So even in a state that does not cover Zepbound for weight loss, Medicaid still covers the FDA-approved uses it must cover, such as Zepbound for obstructive sleep apnea, subject to the state's prior authorization. The states that ended weight-loss coverage in 2026 list sleep apnea among the uses still covered (see the next table).
Sources: NBC San Diego / CNBC: Medicare can now cover Zepbound for sleep apnea, CMS says (January 8, 2025); KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026). Read October 30, 2026.
States that ended coverage in 2026
These programs stopped covering GLP-1s, including Zepbound, for weight loss in 2026. Utah is marked not confirmed: its coverage was funded for fiscal year 2026 only, and no primary source confirms the end.
| State | Weight-loss coverage | Still covered, or notes | Source | Date |
|---|---|---|---|---|
| California | No (ended Jan 1, 2026) | Case-by-case prior authorization for Wegovy (MASH or cardiovascular disease), Zepbound (sleep apnea) and under-21s (EPSDT) | Medi-Cal Rx alert | Oct 21, 2025 |
| Massachusetts | Ended Jul 3, 2026 | Still covered with prior authorization: cardiovascular (BMI over 27 with cardiovascular disease), MASH, sleep apnea (BMI over 30), under-21s (EPSDT) | MassHealth Prescriber e-Letter | Mar 2026 (corrected) |
| New Hampshire | No (ended Jan 1, 2026) | Covers some non-GLP-1 weight-loss drugs | KFF; Milliman | Jan 16, 2026; Mar 19, 2026 |
| Pennsylvania | No for adults 21+ (ended Jan 1, 2026) | Under-21s (EPSDT) continue; type 2 diabetes, sleep apnea, cardiovascular and MASH uses covered with prior authorization | PHLP; KFF | Dec 22, 2025; Jan 16, 2026 |
| Rhode Island | Ended Oct 1, 2026 | Wegovy (cardiovascular or MASH), Zepbound (sleep apnea), type 2 diabetes GLP-1s and under-21s (EPSDT) remain covered | Point32Health RITogether notice; American Diabetes Association | Sep 2026; Jun 25, 2026 |
| South Carolina | No (ended; Jan 1, 2026 per Milliman) | None stated | KFF; Milliman | Jan 16, 2026; Mar 19, 2026 |
| Utah | Not confirmed (likely ended Jun 30, 2026) | KFF: funding limited to fiscal year 2026. The state's prior authorization form (last updated Jul 1, 2025): BMI 30 or higher, or 27 to 29.9 with a related condition, plus a 6-month dietitian-led lifestyle program. No primary source confirms the end. | KFF; Utah Medicaid PA form | Jan 16, 2026; Jul 1, 2025 |
Every other state
Pending, not live: Indiana: No; planned via BALANCE (not confirmed live). Announced Jul 30, 2026. Start date and criteria not published. Louisiana: No (KFF); law pending funding. Covers some non-GLP-1 weight-loss drugs. SB 433 (enrolled) takes effect only when funded; the fiscal note assumes Jan 1, 2027. Signature not confirmed.
No weight-loss coverage found: Alabama, Alaska, Arizona, Arkansas, Colorado, Connecticut, Florida, Georgia, Hawaii, Idaho, Illinois, Iowa, Kentucky, Maine, Maryland, Montana, Nebraska, Nevada, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, South Dakota, Texas, Vermont, Washington, West Virginia and Wyoming. These were not among the 13 fee-for-service programs KFF counted as covering in January 2026, and we found no change since. KFF counts fee-for-service only, so a managed care plan may differ.
Not confirmed: District of Columbia. We found no source for this program.
Sources: KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026); Pew Research Center: Most states don't cover GLP-1s for obesity treatment under Medicaid (January 23, 2026); Milliman: The evolving landscape of obesity coverage in Medicaid (March 19, 2026). Read October 30, 2026.
How to get Zepbound covered by Medicaid
- Every covering state uses prior authorization, so your prescriber applies for you; you cannot apply on your own.
- Several states add conditions: a documented lifestyle program (Mississippi, Utah, Wisconsin), at least 5% weight loss to renew (Delaware, Mississippi, Tennessee, Utah) or trying other medicines first (Virginia, Michigan).
- The CMS BALANCE model lets states opt in, from May 2026 through January 1, 2027, to cover Mounjaro, Ozempic, Rybelsus, Wegovy, the Zepbound KwikPen and Foundayo for weight management under negotiated criteria, including prior authorization; coverage is not guaranteed. CMS's page lists no participating state yet. Indiana has announced it will join; its start date is not confirmed.
Sources: KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026); CMS: BALANCE model (page last modified September 29, 2026); CMS press release: CMS launches voluntary model to expand access to life-changing medicines (December 23, 2025). Read October 30, 2026.
If you are on Medicaid and it does not cover Zepbound
The Medicare GLP-1 Bridge is for Medicare only. It needs Medicare drug coverage: a standalone Part D plan (PDP), a Medicare Advantage plan with drug coverage (HMO, HMO-POS, local or regional PPO), a Special Needs Plan, an employer group waiver plan (EGWP) or LI NET. Medicaid on its own does not qualify. If you have both Medicare and Medicaid with qualifying Part D coverage, you can use the Bridge for the Zepbound KwikPen (not vials) from July 1, 2026 to December 31, 2027 if you meet its criteria; the copay is the full $50 a month, because Extra Help does not apply, and whether your state Medicaid program pays it varies (Pennsylvania's will not, PHLP, June 26, 2026). See does Medicare cover Zepbound?
Sources: Medicare.gov: Weight loss drugs (no page date); CMS: Medicare GLP-1 Bridge (page last modified July 13, 2026); Medicare.gov fact sheet: Medicare GLP-1 Bridge (CMS Product No. 12234) (June 2026); PHLP: New Medicare program to offer limited coverage for GLP-1 weight loss medications (June 26, 2026). Read October 30, 2026.
Buy direct from the manufacturer. Eli Lilly sells Zepbound through LillyDirect for cash, with a prescription you already hold. We list these prices for information; PCF has no commercial relationship with the manufacturer.
- LillyDirect lists the Zepbound KwikPen at $299 a month at the starting dose, checked November 19, 2026. No membership printed, pen needles sold separately, prescription required. LillyDirect's page
- LillyDirect lists the Zepbound vial at $299 a month at the starting dose, checked November 19, 2026. No membership printed, needles and syringes sold separately, prescription required. LillyDirect's page
Higher doses cost more; every dose and seller is in what Zepbound costs without insurance. Compounded tirzepatide, the active ingredient in Zepbound, is sold for cash by US telehealth programs; compounded medicines are not FDA approved and are different products from Zepbound. See what compounded tirzepatide costs per month.
Frequently asked questions
Does Medicaid cover Zepbound for weight loss?
Only in some states. As of October 30, 2026, 10 state Medicaid programs cover GLP-1s such as Zepbound for weight loss, all with prior authorization: Delaware, Kansas, Minnesota, Mississippi, Missouri, North Carolina, Tennessee and Wisconsin, and Michigan and Virginia with much tighter criteria. Most states do not.
Which state Medicaid programs name Zepbound in their criteria?
Delaware, Mississippi, North Carolina and Tennessee name Zepbound in the criteria we read. In North Carolina, Zepbound needs a Wegovy trial first. The other covering programs' criteria either do not name it or were not verified.
Does Medicaid cover Zepbound for sleep apnea?
Medicaid still covers the FDA-approved uses it must cover, such as Zepbound for obstructive sleep apnea, subject to the state's prior authorization. Where the manufacturer has a rebate agreement, states must cover Zepbound for obstructive sleep apnea (CMS, January 2025), even if they do not cover it for weight loss.
Which states stopped covering Zepbound for weight loss in 2026?
California, New Hampshire, Pennsylvania (adults 21 and over) and South Carolina from January 1, 2026, Massachusetts from July 3, 2026 and Rhode Island from October 1, 2026. Utah's coverage was funded for fiscal year 2026 only and likely ended on June 30, 2026, but no primary source confirms it.
Can I use the Medicare GLP-1 Bridge if I have Medicaid?
Only if you also have Medicare with qualifying drug coverage, such as a Part D plan or a Dual Eligible Special Needs Plan: the Bridge is a Medicare program, so Medicaid on its own does not qualify. People with both can use it for the Zepbound KwikPen (not vials) if they meet its criteria, and pay the full $50 a month, because Extra Help does not apply.
How much does Zepbound cost if Medicaid will not cover it?
LillyDirect lists the Zepbound KwikPen at $299 a month at the starting dose, checked November 19, 2026. No membership printed, pen needles sold separately, prescription required. LillyDirect lists the Zepbound vial at $299 a month at the starting dose, checked November 19, 2026. No membership printed, needles and syringes sold separately, prescription required. Higher doses cost more.
Is any state adding coverage?
Indiana announced on July 30, 2026 that it will join the CMS BALANCE model and cover GLP-1s for obesity, but its start date and criteria are not published. Louisiana passed a law requiring coverage once it is funded; the fiscal note assumes January 1, 2027. Neither is live.
Main sources
Last checked October 30, 2026.
- KFF: Medicaid coverage of and spending on GLP-1s (January 16, 2026)
- Pew Research Center: Most states don't cover GLP-1s for obesity treatment under Medicaid (January 23, 2026)
- NBC San Diego / CNBC: Medicare can now cover Zepbound for sleep apnea, CMS says (January 8, 2025)
- Milliman: The evolving landscape of obesity coverage in Medicaid (March 19, 2026)
- CMS: BALANCE model (page last modified September 29, 2026)
- Medicare.gov: Weight loss drugs (no page date)
- LillyDirect: Zepbound self-pay pricing (September 2, 2026)